228 related articles for article (PubMed ID: 25505296)
1. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013.
Kalkowska DA; Duintjer Tebbens RJ; Grotto I; Shulman LM; Anis E; Wassilak SG; Pallansch MA; Thompson KM
J Infect Dis; 2015 Jun; 211(11):1800-12. PubMed ID: 25505296
[TBL] [Abstract][Full Text] [Related]
2. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.
Thompson KM; Kalkowska DA; Duintjer Tebbens RJ
Vaccine; 2015 Mar; 33(13):1568-77. PubMed ID: 25701673
[TBL] [Abstract][Full Text] [Related]
3. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
[TBL] [Abstract][Full Text] [Related]
4. Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India.
Kalkowska DA; Duintjer Tebbens RJ; Thompson KM
J Infect Dis; 2014 Nov; 210 Suppl 1():S398-411. PubMed ID: 25316861
[TBL] [Abstract][Full Text] [Related]
5. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria.
Kalkowska DA; Duintjer Tebbens RJ; Thompson KM
J Infect Dis; 2014 Nov; 210 Suppl 1():S412-23. PubMed ID: 25316863
[TBL] [Abstract][Full Text] [Related]
6. Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination.
Kalkowska DA; Duintjer Tebbens RJ; Pallansch MA; Cochi SL; Wassilak SG; Thompson KM
BMC Infect Dis; 2015 Feb; 15():66. PubMed ID: 25886823
[TBL] [Abstract][Full Text] [Related]
7. Modeling the spread of polio in an IPV-vaccinated population: lessons learned from the 2013 silent outbreak in southern Israel.
Yaari R; Kaliner E; Grotto I; Katriel G; Moran-Gilad J; Sofer D; Mendelson E; Miller E; Huppert A; ; Anis E; Kopel E; Manor Y; Mor O; Shulman L; Singer R; Weil M
BMC Med; 2016 Jun; 14(1):95. PubMed ID: 27334457
[TBL] [Abstract][Full Text] [Related]
8. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
[TBL] [Abstract][Full Text] [Related]
9. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine.
Famulare M; Selinger C; McCarthy KA; Eckhoff PA; Chabot-Couture G
PLoS Biol; 2018 Apr; 16(4):e2002468. PubMed ID: 29702638
[TBL] [Abstract][Full Text] [Related]
10. Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015.
Diop OM; Burns CC; Sutter RW; Wassilak SG; Kew OM;
MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(23):640-6. PubMed ID: 26086635
[TBL] [Abstract][Full Text] [Related]
11. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
Orenstein WA;
Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
[TBL] [Abstract][Full Text] [Related]
12. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep; 1997 Jan; 46(RR-3):1-25. PubMed ID: 9026708
[TBL] [Abstract][Full Text] [Related]
13. Modeling the dynamics of oral poliovirus vaccine cessation.
Thompson KM; Duintjer Tebbens RJ
J Infect Dis; 2014 Nov; 210 Suppl 1():S475-84. PubMed ID: 25316870
[TBL] [Abstract][Full Text] [Related]
14. Progress toward poliomyelitis eradication--Chad, January 2011-August 2012.
Centers for Disease Control and Prevention
MMWR Morb Mortal Wkly Rep; 2012 Oct; 61(42):858-62. PubMed ID: 23095955
[TBL] [Abstract][Full Text] [Related]
15. Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations.
Duintjer Tebbens RJ; Pallansch MA; Cochi SL; Ehrhardt DT; Farag NH; Hadler SC; Hampton LM; Martinez M; Wassilak SGF; Thompson KM
Risk Anal; 2018 Aug; 38(8):1701-1717. PubMed ID: 29314143
[TBL] [Abstract][Full Text] [Related]
16. Anomalous observations on IPV and OPV vaccination.
John TJ
Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
[TBL] [Abstract][Full Text] [Related]
17. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response.
Thompson KM; Wallace GS; Tebbens RJ; Smith PJ; Barskey AE; Pallansch MA; Gallagher KM; Alexander JP; Armstrong GL; Cochi SL; Wassilak SG
Public Health Rep; 2012; 127(1):23-37. PubMed ID: 22298920
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Proactive and Reactive Strategies for Polio Eradication Activities in Pakistan and Afghanistan.
Duintjer Tebbens RJ; Thompson KM
Risk Anal; 2019 Feb; 39(2):389-401. PubMed ID: 30239026
[TBL] [Abstract][Full Text] [Related]
19. Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization.
Thompson KM; Kalkowska DA; Kidd SE; Burns CC; Badizadegan K
Vaccine; 2024 Feb; 42(4):819-827. PubMed ID: 38218668
[TBL] [Abstract][Full Text] [Related]
20. Genetic analysis and characterization of wild poliovirus type 1 during sustained transmission in a population with >95% vaccine coverage, Israel 2013.
Shulman LM; Martin J; Sofer D; Burns CC; Manor Y; Hindiyeh M; Gavrilin E; Wilton T; Moran-Gilad J; Gamzo R; Mendelson E; Grotto I; ;
Clin Infect Dis; 2015 Apr; 60(7):1057-64. PubMed ID: 25550350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
